Abstract

The purpose of the Office of Human Research Services (OHRS) is to enable and enhance clinical and translational research across the consortium by providing Rutgers Cancer Institute of New Jersey (CINJ) members with centralized resources, information and expertise in clinical research. OHRS has the responsibility of working with clinical investigators to manage the business, clinical and regulatory functions of all phases of pediatric and adult interventional/non-interventional trials at CINJ. The current organizational structure is comprised of approximately 70 FTEs and six functional offices including clinical operations, quality assurance, and regulatory affairs. The activity and use of OHRS parallels the growth of the center and has increased as the number of CINJ investigators and oncology faculty increased. In the most recent grant period (2011-2017) the OHRS managed enrollment of 26,432 patients, compared to the seven-year interval corresponding to the previous grant period (2004-2010) in which 11,454 patients were enrolled. Currently, there are 154 active enrolling trials (92 therapeutic) supported by the OHRS. Given an overall Center initiative to enhance translation of center science, OHRS has increased its support for investigator-initiated and multi-center trials and continues to be used extensively by CINJ members.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-22
Application #
10112888
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901

  Publications

Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Celià-Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821

Showing the most recent 10 out of 775 publications